Search the Newsreel

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Oppenheimer downgrades Legend Biotech stock rating on M&A concerns

Oppenheimer downgraded Legend Biotech (NASDAQ:LEGN) to Perform from Outperform, lowering its price target to $40 due to diminished M&A prospects, particularly after Johnson & Johnson was removed as a potential buyer. The firm also cited concerns over the CEO's departure, financing issues, and weak …

Green Fresh Biotechnology Narrows Interim Loss on Strong Carrageenan Sales

RBC Adjusts Price Target on Legend Biotech to $58 From $59, Maintains Outperform Rating

RBC Capital Markets has adjusted its price target for Legend Biotech (LEGN) to $58, down from $59, while reiterating an Outperform rating on the stock. This revision comes amidst recent news for Legend Biotech, including a downgrade from Oppenheimer and the company reporting its …

Legend Biotech Releases Q2 2026 Financial Results

Legend Biotech (LEGN) reported strong Q2 2026 financial results, with adjusted earnings of $0.16 per share, surpassing estimates. The company generated $387.5 million in revenue, largely driven by its CARVYKTI collaboration, indicating significant growth and market penetration for its cell therapy platform. Wall Street …

Legend Turns Profitable In Q2 As CARVYKTI Sales Jump By 50%

(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driven by higher collaboration revenue and improved operating income. For …

Legend Biotech (LEGN) Stock Rebounds As Profit Arrives But Carvykti Risk Persists

Legend Biotech (LEGN) Returned To Profit, Is The Stock Still Cheap?

PDS Biotechnology Halts PDS0101 Trial, Pivots to PDS0301 in Colorectal Cancer

PDS Biotechnology has announced the halt of its PDS0101 trial and internal investment, including the discontinuation of the Phase 3 VERSATILE-003 trial, to pivot its resources towards PDS0301. PDS0301, a tumor-targeted IL-12 immunocytokine, will now be the company's lead asset with a priority indication …

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relations - Caroline LeCates Paul TAKEAWAYS Worldwide Net …

Avecho Biotechnology Cuts Shareholder Numbers via Small Holding Sale Facility

RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger

FBIO Looks 125.0% Overvalued on GF Value™ Ahead of Q2 Earnings

Fortress Biotech (NASDAQ: FBIO) is set to release its Q2 earnings report on August 12, 2026, with analysts forecasting an EPS of -$0.20 and revenue of $18.3 million. The stock is currently deemed 125.0% overvalued by GuruFocus' GF Value™ metric, trading at $2.61 against …

Legend Biotech Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LEGN) 2026-08-11

This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …

Windlas Biotech Shares Surge Over 12% Following Strong Q1 Top-Line Growth

Legend Biotech Corp (LEGN) (Q2 2026) Earnings Call Highlights: First Profitable Quarter Driven ...

This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotechnology Corporation's stock crashed by approximately 67% after the company announced a strategic refocus of its resources towards the PDS0301 program for metastatic colorectal cancer. This shift is based on encouraging clinical data and a belief that PDS0301 offers a more attractive path …

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Legend Biotech (NASDAQ:LEGN) surged 6% after reporting its first-ever profitable quarter in Q2 2026, with revenue of $387.5 million beating estimates and adjusted EPS of $0.16 doubling consensus. The strong performance was driven by CARVYKTI net sales reaching $657 million, up 50% year-over-year, and …

PDS Biotech to report quarterly financial results

PDS Biotech has scheduled the release of its quarterly financial results for the quarter ending June 30, 2026, on August 13, 2026. This announcement was initially published by PDS Biotechnology Corporation via GlobeNewswire. The news brief was created by Public Technologies (PUBT) using generative …

Earnings Flash (LEGN) Legend Biotech Corporation Reports Q2 Revenue $387.5M, Vs. FactSet Est of $356.0M

Legend Biotech Corporation (LEGN) reported strong financial results for Q2, with revenues reaching $387.5 million, significantly surpassing the FactSet estimate of $356.0 million. This earnings flash highlights the company's robust revenue performance for the quarter.

Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings

Avecho Biotechnology Limited (ASX:AVE) Share Market Overview and Biotechnology Sector Profile

Legend Biotech Q2 Earnings Call Highlights

Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CARVYKTI sales rose sharply: Worldwide net trade sales increased 50% year over year to approximately $657 million, driven by earlier-line treatment adoption in the U.S. and international expansion …

Genscript Highlights Legend Biotech’s Q2 Results and Cautions Investors

Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5%

Legend Biotech reported stronger-than-expected Q2 2026 results, achieving its first quarter of company-wide profitability with adjusted earnings of $0.16 per share and revenue of $387.5 million, significantly beating analyst estimates. The company's lead CAR-T therapy, CARVYKTI, saw worldwide net trade sales increase 50% year-over-year, …

Form 8K PDS Biotechnology Corp For: 11 August By Investing.com

This article announces the filing of a Form 8K by PDS Biotechnology Corp for August 11, as reported by Investing.com. It provides a brief update on company filings without further details on the content of the Form 8K. The article appears to be a …

PDS0301 Data Show 80% 24-Month Survival With Liver Metastases

PDS Biotechnology (Nasdaq: PDSB) announced a strategic refocus, prioritizing its tumor-targeted IL-12 immunocytokine PDS0301 and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, instead seeking strategic partnerships for PDS0101. This decision follows promising Phase 2 data for PDS0301 in metastatic colorectal cancer …

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma will take the reins of a young startup …

Legend Biotech stock rises 5% on earnings and revenue beat

Pipette dropping liquid into a test tube ©Adobe Stock Images Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5.5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnings and revenue, supported by continued growth in CARVYKTI sales. Adjusted earnings came in at …

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Legend Biotech USA Inc. CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, …

Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed

Sana Biotechnology (SANA) reported narrower losses in Q2 2026 and announced a US$25 million equity deal with the Mayo Clinic, contributing to a 13.5% stock increase. The company also made progress in its clinical programs and unveiled promising data for its UP421 cell therapy. …

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment …

Why Did Adaptive Biotechnologies (ADPT) Move After Its Latest Update?

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

Windlas Biotech Standalone June 2026 Net Sales at Rs 248.10 crore, up 18.09% Y-o-Y

Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Veraxa Biotech AG Ord Shs (VRXA), detailing its future EPS and Revenue Growth Estimates. It includes current stock performance data, market capitalization, and a peer comparison with other biotechnology and medical research companies. The financial forecasting sections …